CoverageForm 410-K10-Q8-K13D13G13F

PETS · Petmed Express Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · PETS

Income Statement

Line itemQ3 '26Q2 '26Q1 '26Q1 '25Q3 '25Q2 '25Q1 '24Q3 '24Q2 '24Q1 '23
Revenue$40.66M$44.36M$51.18M$78.24M$65.32M$71.00M----
Cost of Revenue-$31.95M$36.78M$49.98M$38.08M$42.26M$55.72M$47.43M$50.94M$50.24M
Gross Profit$9.46M$12.41M$14.40M$17.97M$14.91M$17.31M$22.53M$17.88M$20.06M$19.94M
R&D----------
SG&A$12.19M$14.18M$12.95M$4.87M$10.79M$10.49M$15.71M$13.43M$13.28M$9.35M
Total Operating Expenses$19.93M$20.80M$48.53M$13.59M$15.36M$16.76M$24.65M$20.96M$20.50M$16.45M
D&A$2.40M$2.28M$2.28M$1.72M$1.59M$1.66M$753.0K$941.0K$858.0K$753.0K
Operating Income($10.47M)($8.38M)($34.13M)$4.39M($450.0K)$554.0K($2.13M)($3.07M)($441.0K)$3.49M
Interest Expense$400.0K---------
Income Tax$11.0K$9.0K$9.0K$958.0K$465.0K($1.40M)($115.0K)($618.0K)$453.0K$1.03M
Net Income($10.55M)($8.52M)($34.15M)$3.75M($707.0K)$2.33M($887.0K)($2.03M)($70.0K)$2.77M
EPS - Basic($0.50)($0.41)($1.65)$0.18($0.03)$0.11($0.04)($0.10)$0.00$0.14
EPS - Diluted($0.50)($0.41)($1.65)$0.18($0.03)$0.11($0.04)($0.10)$0.00$0.14

Balance Sheet

Line itemQ3 '26Q2 '26Q1 '26Q1 '25Q3 '25Q2 '25Q1 '24Q3 '24Q2 '24Q1 '23
Cash & Equivalents$26.91M$36.10M$41.13M$54.72M$50.10M$52.05M$55.30M$49.44M$53.47M$104.09M
Accounts Receivable$1.56M$1.97M$1.60M$2.32M$2.26M$1.62M$3.28M$1.93M$2.17M$1.74M
Inventory$12.21M$14.77M$18.36M$16.20M$11.79M$28.56M----
Accounts Payable$20.30M$19.12M$20.04M$23.56M$10.95M$16.95M$37.02M$38.85M$25.38M$25.21M
Current Assets$48.51M$59.45M$67.89M$78.87M$68.38M$70.78M$93.65M$95.55M$85.66M$131.45M
Total Assets$87.97M$100.30M$109.84M$148.70M$144.79M$146.03M$169.88M$173.35M$159.27M$164.12M
Current Liabilities$54.77M$56.68M$57.62M$62.77M$47.96M$48.83M$72.16M$72.40M$40.70M$36.50M
Long-term Debt----------
Total Liabilities$55.20M$57.24M$58.29M$63.57M$48.61M$49.60M$73.15M$73.29M$45.60M$40.32M
Stockholders' Equity$32.77M$43.06M$51.55M$85.13M$96.18M$96.43M$96.73M$100.06M$113.67M$123.80M
Retained Earnings$13.32M$23.87M$32.39M$66.54M$78.19M$78.89M$71.56M$76.56M$91.88M$105.49M

Cash Flow

Line itemQ3 '26Q2 '26Q1 '26Q1 '25Q3 '25Q2 '25Q1 '24Q3 '24Q2 '24Q1 '23
Operating Cash Flow--($12.27M)($8.52M)--$562.0K--$6.38M
Investing Cash Flow--($1.29M)($683.0K)--($37.01M)--($5.98M)
Financing Cash Flow--($30.0K)($104.0K)--($6.10M)--($6.06M)
CapEx--$1.29M$683.0K--$1.15M--$982.0K
Free Cash Flow--($13.56M)($9.20M)--($591.0K)--$5.40M

Ratios

MetricQ3 '26Q2 '26Q1 '26Q1 '25Q3 '25Q2 '25Q1 '24Q3 '24Q2 '24Q1 '23
Profitability
Gross margin23.3%28.0%28.1%23.0%22.8%24.4%----
Operating margin-25.7%-18.9%-66.7%5.6%-0.7%0.8%----
EBITDA margin-19.8%-13.8%-62.2%7.8%1.7%3.1%----
Net margin-26.0%-19.2%-66.7%4.8%-1.1%3.3%----
Free cash flow margin---26.5%-11.8%------
FCF / Net income--0.40-2.45--0.67--1.95
R&D / Revenue----------
SG&A / Revenue30.0%32.0%25.3%6.2%16.5%14.8%----
Effective tax rate---20.3%--151.5%--118.3%27.1%
Return on assets-12.0%-8.5%-31.1%2.5%-0.5%1.6%-0.5%-1.2%-0.0%1.7%
Return on equity-32.2%-19.8%-66.3%4.4%-0.7%2.4%-0.9%-2.0%-0.1%2.2%
Return on invested capital----------
Liquidity
Current ratio0.891.051.181.261.431.451.301.322.103.60
Quick ratio0.660.790.861.001.180.861.301.322.103.60
Cash ratio0.490.640.710.871.041.070.770.681.312.85
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage-26.2x---------
Equity multiplier2.682.332.131.751.511.511.761.731.401.33
Liabilities / Assets0.630.570.530.430.340.340.430.420.290.25
Efficiency
Asset turnover0.460.440.470.530.450.49----
Inventory turnover-2.162.003.083.231.48----
Days sales outstanding14d16d11d11d13d8d----
Days inventory outstanding-169d182d118d113d247d----
Days payable outstanding-218d199d172d105d146d243d299d182d183d
Cash conversion cycle--34d-5d-43d21d109d----
Valuation
P / E---23.3x-33.5x---116.0x
P / B2.1x1.2x1.3x1.0x1.0x0.8x1.0x1.5x1.8x2.7x
P / S1.7x1.2x1.3x1.1x1.5x1.1x----
EV / EBITDA---5.4x43.4x11.3x--372.8x53.1x
Growth
Revenue growth (YoY)-37.7%-37.5%-34.6%-------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)-36.6%-28.3%-19.9%-20.2%-16.6%-13.7%13.0%17.4%8.7%-8.4%
Operating income growth (YoY)-2226.4%---85.4%---299.7%--35.6%
Net income growth (YoY)-1392.6%---65.1%---10568.4%--37.3%
EPS growth (YoY)-1566.7%---70.0%-----36.4%
EPS CAGR (3y)----6.5%--29.2%----18.6%
EPS CAGR (5y)----7.1%--19.7%----20.8%
FCF growth (YoY)---47.4%-1456.7%------
FCF CAGR (5y)----------17.2%
Book value growth (YoY)-65.9%-55.3%-39.5%-12.0%-3.9%-15.2%-21.9%-25.1%-17.7%-12.9%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2026-03-31.

Business segments

$179.02M total
Reportable Segment$179.02M · 100.0%

Product / service

$4.50M total
Partner Program$4.50M · 100.0%

Peer comparison

Same SIC group: Retail-Drug Stores and Proprietary Stores

CompanyRevenue (last FY)Net marginROE
CVS$402.07B0.4%2.4%
WBA---
GRDN$1.23B-9.0%-50.5%
MDVL$43.11M-110.5%-228.7%
CVET$4.58B-1.2%-3.6%

Comparing PETMED EXPRESS INC against the 5 most active filers in the same SIC group.

Dividends

$0.00/share trailing 12 months

Ex-datePer share
Aug 11, 2023$0.3000
Jun 5, 2023$0.3000
Feb 16, 2023$0.3000
Nov 17, 2022$0.3000
Aug 11, 2022$0.3000
May 19, 2022$0.3000
Feb 4, 2022$0.3000
Nov 5, 2021$0.3000
Aug 5, 2021$0.3000
May 13, 2021$0.3000
Jan 29, 2021$0.2800
Nov 6, 2020$0.2800
Jul 30, 2020$0.2800
May 14, 2020$0.2800
Jan 31, 2020$0.2700
Nov 1, 2019$0.2700
Aug 1, 2019$0.2700
May 16, 2019$0.2700
Feb 1, 2019$0.2700
Nov 2, 2018$0.2700
Aug 2, 2018$0.2700
May 17, 2018$0.2500
Feb 2, 2018$0.2500
Nov 3, 2017$0.2000